DC-9476 (BRD4-BD2 inhibitor)
Rheumatoid Arthritis, Still's Disease, Hidradenitis Suppurativa
IND-EnablingActive
Key Facts
Indication
Rheumatoid Arthritis, Still's Disease, Hidradenitis Suppurativa
Phase
IND-Enabling
Status
Active
Company
About DeepCure
DeepCure is a private, preclinical-stage biotech applying a proprietary AI/ML and physics-integrated platform to drug difficult targets in immunology. The company has identified its first two development candidates: DC-9476, an oral BRD4-BD2 inhibitor for rheumatoid arthritis and related conditions, and DC-15442, an oral STAT6 inhibitor for asthma and atopic dermatitis, both in IND-enabling studies. With a leadership team combining deep AI expertise from MIT with seasoned drug development experience from major pharma, DeepCure aims to create a new class of oral therapies for diseases dominated by injectable biologics.
View full company profile